Article
Oncology
Dong Hyun Lee, Hyuna Cho, Eun Young Choi, Min Kim
Summary: Most posterior scleritis patients were of non-infectious type and some needed additional immunosuppressive treatment. In patients with a history of ocular surgery or trauma, especially with the presence of pus-containing nodules, infectious posterior scleritis should always be considered.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Review
Ophthalmology
Francesco Pichi, Andre Luiz Land Curi, Daniel Vitor Vasconcelos-Santos, Alessandro Marchese, Maria Vittoria Cicinelli, Elisabetta Miserocchi, Ariel Schlaen
Summary: OCT can identify different features of infectious uveitis in the vitreous, retina, and choroid, which are helpful for differential diagnosis and treatment evaluation.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Article
Ophthalmology
Federico Zicarelli, Aniruddha Agarwal, Chiara Rizzi, Marta Oldani, Giovanni Staurenghi, Alessandro Invernizzi
Summary: This study assessed the changes in retinal vein and artery diameters during active and inactive intraocular inflammation in eyes with uveitis. The results showed that active inflammation could influence the diameters of retinal veins and arteries, but they decreased when the inflammation wore off.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2023)
Article
Medicine, General & Internal
Masaru Takeuchi, Yoshihiko Usui, Kenichi Namba, Hiroshi Keino, Masaki Takeuchi, Hiroshi Takase, Koju Kamoi, Keitaro Hase, Takako Ito, Kei Nakai, Kazuichi Maruyama, Eri Kobayashi, Hisashi Mashimo, Tomohito Sato, Nobuyuki Ohguro, Junko Hori, Annabelle A. Okada, Koh-hei Sonoda, Nobuhisa Mizuki, Hiroshi Goto
Summary: This retrospective study evaluated the 10-year outcome of infliximab (IFX) treatment for uveitis in Behcet disease patients. The results showed that approximately 75% of patients continued IFX treatment for 10 years, and their visual acuity significantly improved and remained stable. Although half of the patients experienced recurrence of uveitis after treatment, there was no significant difference in visual acuity compared to those without recurrence.
FRONTIERS IN MEDICINE
(2023)
Article
Ophthalmology
Jamel Corredores Dieb, Brice Vofo, Radgonde Amer
Summary: This study retrospectively evaluated the efficacy and long-term effects of infliximab and adalimumab in patients with refractory NIPPU. The results showed that anti-TNF-alpha therapy effectively controlled ocular inflammation and reduced flare rate. Early introduction of anti-TNF-alpha therapy and the use of adalimumab were associated with a lower risk of visual loss.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2022)
Article
Biochemistry & Molecular Biology
Tedi Begaj, Amy Yuan, Ines Lains, Ashley Li, Samuel Han, Gayatri Susarla, Ravi Parikh, Lucia Sobrin
Summary: This study found that choroidal caverns (CCs) may be a complication in patients with chronic non-infectious uveitis (NIU), especially in those with multifocal choroiditis (MFC) and male patients.
Article
Medicine, General & Internal
Yu Yoneda, Yoshihiko Usui, Rie Tanaka, Keitaro Hase, Kenichi Namba, Koju Kamoi, Hiroshi Takase, Masaki Takeuchi, Wataru Matsumiya, Sentaro Kusuhara, Atsunobu Takeda, Nobuyo Yawata, Ryoji Yanai, Tomona Hiyama, Yosuke Harada, Noriyasu Hashida, Kazuichi Maruyama, Kei Nakai, Ryo Taguchi, Toshikatsu Kaburaki, Nobuhisa Mizuki, Hiroshi Goto, Yujiro Fujino, Masaru Takeuchi
Summary: A retrospective review of medical records of 160 patients diagnosed with Fuchs' uveitis syndrome (FUS) in Japan revealed that the ocular findings were consistent with characteristic features of FUS, but the low prevalence of FUS in Japan may be due to being overlooked and misdiagnosed.
FRONTIERS IN MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Sean Teabagy, Emma Wood, Evan Bilsbury, Sean Doherty, Priya Janardhana, Darren J. Lee
Summary: Ocular immune privilege refers to the ability of foreign tissue grafts placed in the eye to survive indefinitely. This privilege is maintained by various mechanisms, including the blood-ocular barrier, lack of lymphatics in the eye, production of immune-suppressing molecules in the ocular microenvironment, and induction of systemic regulatory immunity. Failure of ocular immune privilege can lead to uveitis, which is a group of inflammatory disorders that can cause vision loss. Current treatments for uveitis involve immunosuppressive and anti-inflammatory medications. Research on ocular immune privilege mechanisms and the development of novel uveitis treatments is ongoing.
ADVANCED DRUG DELIVERY REVIEWS
(2023)
Article
Ophthalmology
Eric B. Suhler, Glenn J. Jaffe, Eric Fortin, Lyndell L. Lim, Pauline T. Merrill, Andrew D. Dick, Antoine P. Brezin, Quan Dong Nguyen, Jennifer E. Thorne, Joachim Van Calster, Luca Cimino, Alfredo Adan, Hiroshi Goto, Toshikatsu Kaburaki, Michal Kramer, Albert T. Vitale, Martina Kron, Alexandra P. Song, Jianzhong Liu, Sophia Pathai, Kevin M. Douglas, Ariel Schlaen, Cristina Muccioli, Mirjam E. J. Van Velthoven, Manfred Zierhut, James T. Rosenbaum
Summary: Long-term treatment with adalimumab in patients with noninfectious intermediate, posterior, or panuveitis led to reduced corticosteroid use and increased quiescence, with reported adverse events consistent with the known safety profile of adalimumab.
Review
Medicine, Research & Experimental
Xue Wu, Mengying Tao, Ling Zhu, Ting Zhang, Ming Zhang
Summary: Non-infectious uveitis (NIU) is an eye disorder characterized by inflammation, primarily affecting people of working age. Accurate diagnosis and targeted treatment are crucial for improving patient prognosis.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Medicine, General & Internal
Yosuke Harada, Tomona Hiyama, Yoshiaki Kiuchi
Summary: This single-center retrospective study found that MTX is effective in controlling ocular inflammation for Japanese patients with non-infectious uveitis, but the relatively high incidence of MTX-related adverse effects in the Japanese population emphasizes the need for careful monitoring and dose adjustments for long-term use of this therapy.
FRONTIERS IN MEDICINE
(2021)
Article
Ophthalmology
Yosef Milstein, Elianora Haiimov, Mordechai Slae, Zev Davidovics, Peri Millman, Liron Birimberg-Schwartz, Ariel Benson, Michael Wilschanski, Radgonde Amer
Summary: This study aimed to investigate if patients with non-infectious uveitis (NIU) have an increased risk for celiac disease (CeD). Celiac antibody testing was conducted on 112 patients and it was found that 2 (1.79%) of the NIU patients had positive anti-tTG serology and confirmed CeD. Compared to the expected risk of CeD in the general Israeli population of 0.31%, this resulted in an odds ratio of 5.77 (95% CI 1.4118-23.4737, P=0.049). Three additional patients had positive serology for CeD but were not confirmed.
OCULAR IMMUNOLOGY AND INFLAMMATION
(2023)
Article
Ophthalmology
Nafsika Voulgari, Claire-May Blanc, Vanessa Guido, Daniele C. Rossi, Yan Guex-Crosier, Florence Hoogewoud
Summary: Tick-borne encephalitis (TBE) is a viral infection of the central nervous system, usually transmitted by tick bites. This case report describes a 58-year-old patient with TBE-related uveitis, who experienced complete resolution of symptoms after treatment.
Article
Biology
Zitong Lu, Zhi Geng, Wei Li, Shengyu Zhu, Jinzhu Jia
Summary: This paper discusses the evaluation of causes of effects in the case of a single causal variable and multiple causal variables that can affect each other. We define posterior total and direct causal effects and provide assumptions and identification equations. When causal relationships can be depicted by causal networks, we can simplify the assumptions and equations for identification.
Article
Rheumatology
Waleed A. Hassan, Basma M. Medhat, Maha M. Youssef, Yomna Farag, Noha Mostafa, Alshaimaa R. Alnaggar, Mervat E. Behiry, Rasha A. Abdel Noor, Riham S. H. M. Allam
Summary: The most prevalent causes of non-infectious uveitis were Behcet's disease (51.2%) and idiopathic uveitis (28.9%) in this study. Visual loss (22.3%) was associated with a longer disease duration, lower education level, and prevalent panuveitis.
CLINICAL RHEUMATOLOGY
(2021)
